Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Actuarialon May 17, 2021 9:32am
184 Views
Post# 33213195

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Share price taken down

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Share price taken downAgreed. Makeing a deal before P3 is preferred but it is never a promise nor a sure thing to happen. Negatiation doesn't alway result in a deal because of a lot of things, one of them is price. The only thing so far we have confidence is the science of H2S platform. ATE has enough cash to take 346 through P3 alone even in the worst scenario. Other scenarios can only be better. Nothing truly to worry about. GLTA longs!
MrMugsy wrote:
Yellowknifer69 wrote: Hello and good morning ATE Longs:

Hope all are well and staying Covid-Free.  To the point about heading into P3, I thought I read something from Dan indicating that the Company had no intention of actually starting the clinical trials.  That something would likely transpire well before that time?  Can anybody clarify?

With thanks,

Staying long, no place else to go - literally!  Lol

Yellowknifer


True - they don't want to take OTENA to P3 on their own.
That comment came from Dan years ago - before being fully funded - and it's been echoed by the company since.

I'm sure they would like to strike a deal sooner than later - or a deal in principal - or even a conditional deal ... but ... this is still very fluid and evloving (IMO only).

I don't think they can promise anything as I'm assuming discussions are ongoing - and - they haven't talked to all potential partners yet.


<< Previous
Bullboard Posts
Next >>